Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.14365/5969
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGugu, M.-
dc.contributor.authorAcharya, S.-
dc.contributor.authorPira, D.-
dc.contributor.authorPoletti, S.-
dc.contributor.authordi Flora, A.-
dc.contributor.authorSaksida, T.-
dc.contributor.authorFigueira, I.-
dc.date.accessioned2025-02-25T19:32:17Z-
dc.date.available2025-02-25T19:32:17Z-
dc.date.issued2025-
dc.identifier.issn2732-5121-
dc.identifier.urihttps://doi.org/10.12688/openreseurope.17547.2-
dc.identifier.urihttps://hdl.handle.net/20.500.14365/5969-
dc.description.abstractParkinson’s disease (PD) affects more than one million people in the EU. It currently has no definitive cure, meaning that patients rely only on symptomatic treatments, which themselves are burdened by side effects. The need for advancements in both knowledge and available treatments is thus strongly felt by patients, caregivers, and health operators. This unmet need sparked the idea of orchestrating a collaborative effort via a common network – IMMUPARKNET (The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork). The IMMUPARKNET COST Action focuses on challenges in PD and its related crosstalk with immune response. Although widely recognized, the role of immunity in the onset and development of PD is still unclear. The main goal of IMMUPARKNET is to fill this knowledge gap by establishing an innovative, interdisciplinary research network and fostering exchanges of expertise among specialists from different countries and institutions. As we gather scientists and clinicians who study immunity in PD and related fields, IMMUPARKNET will establish the first nucleus of a multidisciplinary ecosystem that aims to harmonize efforts and approaches, both in research and clinical practice, to boost the development of ground-breaking treatments for PD. Through meetings, training schools, webinars, position papers, and review manuscripts, IMMUPARKNET will lead fruitful exchanges of know-how among experts in the field. The IMMUPARKNET structure revolves around 5 working groups, with a total of 157 active members from 34 different countries. Of these active members, 58.5% are young researchers, while 67.5% come from Inclusiveness Target Countries (ITC - less research-intensive COST Members; https://www.cost.eu/about/members/). IMMUPARKNET output will facilitate the improved sharing and development of research resources, straightening the road to novel treatments and identifying where existing ones can be repurposed, all, ultimately and hopefully, finding a cure for PD. Copyright: © 2025 Gugu M et al.en_US
dc.language.isoenen_US
dc.publisherF1000 Research Ltden_US
dc.relation.ispartofOpen Research Europeen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectImmune Responseen_US
dc.subjectNetworken_US
dc.subjectParkinson'S Diseaseen_US
dc.titleImmunity Unveiled: a Translational Network for Tackling Parkinson's Disease – Immuparkneten_US
dc.typeLetteren_US
dc.identifier.doi10.12688/openreseurope.17547.2-
dc.identifier.scopus2-s2.0-85217444470-
dc.departmentİzmir Ekonomi Üniversitesien_US
dc.authorscopusid57425554200-
dc.authorscopusid57224739314-
dc.authorscopusid58421235000-
dc.authorscopusid59550938400-
dc.authorscopusid58661476000-
dc.authorscopusid46061288700-
dc.authorscopusid6701468226-
dc.identifier.volume4en_US
dc.relation.publicationcategoryDiğeren_US
dc.identifier.scopusqualityQ2-
dc.identifier.wosqualityN/A-
item.openairetypeLetter-
item.grantfulltextnone-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
Appears in Collections:Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Show simple item record



CORE Recommender

Page view(s)

22
checked on Mar 31, 2025

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.